I appreciate your thoughtful reply but disagree. People pay $1oo,ooo for a CA drug to live 2 months longer (on average), why not that much to live 2.5 yrs longer. The anti-diabetic effect may gain further confirmation in the course of a phase 3 kidney disease trial. How good would it be if the drug worked for both in an overlapping population? I will bet that they do find a partner and it is a catalyst for the stock. Thanks, ron
I find the results so far intriguing. It is a huge market, almost unaddressed. There is good preclinical and clinical data to suggest it prevents/slow down fibrosis, the common final pathway.
Really? MCdonald's and their suppliers do not share crucial technology or the same chairman of the board. McDonald's can buy their rolls from anyone, I'm glad you guys appreciate each other. Unfortunately, that doesn't make either of you any smarter.
who owns the manufacturing technology for dc -vax - nwbo or cognate? Has Linda poured nwbo's money into cognate to make cognate the profit center if nwbo succeeds? Can cognate hold that technology hostage, making nwbo totally dependent on it?
you can't recognize incompetent management when it hits you in the face
thank you for your explanation of your thinking and your handle. again, my bad. I do disagree with your suggested multiple (P/e) and your price target. I don't think their competitors are that weak; several have introduced pico instruments recently and have adequate financial resources. I think cost savings is a limited game, though acquisitions should be taken into account in growth. Other technologies could be formidable competitors (zltq). Still, I continue to hold a reasonable number of shares for lack of better alternatives. Long term I am positive, though I have a wait and see attitude.
i should not have been so sarcastic, but your analysis is inadequate and/or slanted if you do not mention or take into account the lack of organic growth, this is why, I believe, the stock is priced the way it is. It has the same lack of large broker analysts it had when it was $30/share. I also don't know
what an "excellent market" means. In fact, competitions seems to be more intense, according to the CEO (and other cos. in the space) and is pressuring margins. The legacy businesses are flat or declining, and innovation is vital for any growth at all. In short, I think the stock market is pretty efficient, though I am holding this co. for the long-term, since it is well-managed and other stocks are expensive too. Note that management (Mike) sold shares around $22 and holds very little stock.
I also think you are overconfident of your analysis, given these considerations, and that irked me.